Anagrelide HCl
PDE2 inhibitor / Potent and selective phosphodiesterase (PDE3) inhibitor, IC50=36 nM).1 Inhibits platelet production by disrupting megakaryocyte maturation2 via a mechanism which is independent of PDE3 inhibition3. Clinically useful agent for conditions requiring platelet lowering therapy.4,5
Biochemicals & reagents
58579-51-4
BL-4162A
1) Gilespie et al. (1988), Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity; Biochem. Pharmacol. 37 2866 2) Mazur et al. (1992), Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans; Blood, 79 1931 3) Wang et al. (2005), Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures; Br. J. Pharmacol., 146 324 4) Barbui et al. (2012), Front-line therapy in polycythemia vera and essential thrombocythemia; Blood Rev., 26 205 5) Chen et al. (2012), Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis; Jpn. J. Clin. Oncol., 42 761
-20°C
TARGET: PDE (Phosphodiesterase) -- PATHWAY: Coagulation; cAMP / cGMP signaling